SEA-CD70
- Generic Name
- SEA-CD70
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70. SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).
- Associated Conditions
- -
- Associated Therapies
- -
Anti CD70 Antibodies Clinical Trials FDA Approval CD70 Cancer Therapies
CD70 inhibitors, emerging in immunotherapy, target immune responses and cellular interactions, with >20 therapies in clinical trials. They offer precision medicine for diseases like cancer and autoimmune disorders, with ongoing trials like SEA-CD70 evaluating safety and efficacy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath